AnaptysBio

BioTech/Drugs - San Diego, CA, US

AnaptysBio Employees
Bruce Randazzo

Vice President Clinical Development

Contact Bruce Randazzo

Daisy Khuu

Associate Director, CMC Analytical Development

Contact Daisy Khuu

Pejman Soroosh

Vice President, Head of Immunology Research

Contact Pejman Soroosh

Liz Chen

Director of Quality Assurance

Contact Liz Chen

Beth Mueller

Senior Vice President Human Resources

Contact Beth Mueller

James McAllister

Senior Director, Regulatory Affairs

Contact James McAllister

View All AnaptysBio Employees Contact All AnaptysBio Employees
AnaptysBio Senior Management
Dennis Mulroy

Chief Financial Officer

Contact Dennis Mulroy

Eric Loumeau

Chief Operating Officer and General Counsel

Contact Eric Loumeau

View All AnaptysBio Employees Contact All AnaptysBio Employees
AnaptysBio Details

AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates to address emerging biological targets using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development and commercialization of our proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights in the United States.Our wholly-owned product pipeline includes etokimab (ANB020) and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. We are advancing etokimab, an antibody that inhibits the activity of interleukin-33, for the treatment of moderate-to-severe adult atopic dermatitis, severe adult eosinophilic asthma, and adult chronic rhinosinusitis with nasal polyps (CRSwNP).In addition, we are developing our ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP).Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in antibody discovery and development, collaborations, operations and corporate finance.Additionally, multiple AnaptysBio-generated antibodies have entered the clinic under our immuno-oncology-focused collaboration with TESARO and inflammation-focused collaboration with Celgene.For more information, visit www.anaptysbio.com.

AnaptysBio logo, AnaptysBio contact details
Website: anaptysbio.com
Employees: 100 - 249
HQ: 858-362-6295
Location: San Diego, CA, US
Revenue: 10 - 20 Million
Antibodies Cancer immunotherapy Inflammation Fibrosis Immunology Biotech SaaS Commercial Physical Research Biotechnology Biotech Pharmaceuticals
AnaptysBio Technologies
Email Providers

Outlook

Domain Name Services

Route 53

CMS

Drupal

Email Delivery

Amazon SES

Other

MailChimp SPF

Hosting

CloudFlare Hosting

View All Technologies Used At AnaptysBio

Contacting AnaptysBio: Connect with Executives and Employees

Get in Touch with AnaptysBio Executives and Employees

Connecting with AnaptysBio's Executives and Workforce

Accessing Contact Information for AnaptysBio Executives

Connecting with AnaptysBio: Reach Out to Their Team

Discover How to Contact AnaptysBio Executives and Staff

Looking to connect with AnaptysBio executives or employees?

Seeking to Get in Touch with AnaptysBio Executives or Staff?

Want to Reach Out to AnaptysBio Executives or Team Members?

In Search of Contact Details for AnaptysBio Professionals?

Connecting with AnaptysBio: Contacting Executives and Staff

Browse companies
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z